Please ensure Javascript is enabled for purposes of website accessibility

US Supreme Court Lets Parents Take Kids Out of Classes With LGBT Storybooks

30 minutes ago

In Win for Trump, US Supreme Court Limits Judges’ Power to Block Birthright Citizenship Order

2 hours ago

California’s Newsom Sues Fox News for $787 Million for Defamation Over Trump Call

2 hours ago

Motorcycle Collides With Tractor in Fatal Fresno County Collision

2 hours ago

Fourth of July Celebrations Begin Saturday. Here’s Your Fresno Area Guide

4 hours ago

Bill Moyers, Broadcaster and LBJ’s White House Press Secretary, Dies at 91

21 hours ago

State Department Approves $30 Million for Gaza Humanitarian Foundation

22 hours ago

Cargo Ship That Caught Fire Carrying Electric Vehicles Sinks in the Pacific

1 day ago

4 Million Acres of California Forests Could Lose Protection. What Trump’s ‘Roadless Rule’ Repeal Could Do

2 days ago
WHO Study Finds Remdesivir Didn't Help COVID-19 Patients
gvw_ap_news
By Associated Press
Published 5 years ago on
October 16, 2020

Share

GENEVA — A large study led by the World Health Organization suggests that the antiviral drug remdesivir did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries.

The results announced Friday do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival.

The drug has not been approved for COVID-19 in the U.S., but it was authorized for emergency use after the previous study found it shortened recovery time by five days on average. It’s approved for use against COVID-19 in the United Kingdom and Europe, and is among the treatments U.S. President Donald Trump received when he was infected earlier this month.

The WHO study involved more than 11,000 patients in 30 countries. About 2,750 were randomly assigned to get remdesivir. The rest got either the malaria drug hydroxychloroquine, the immune-system booster interferon, the antiviral combo lopinavir-ritonavir, or just usual care. The other drugs have largely been ruled out for COVID-19 by previous studies, but not remdesivir.

“In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)”

The Results Have Not Been Published in a Journal or Reviewed by Independent Scientists

Death rates after 28 days, the need for breathing machines and time in the hospital were relatively similar for those given remdesivir versus usual care.

The results have not been published in a journal or reviewed by independent scientists, but were posted on a site researchers use to share results quickly.

“The big story is the finding that remdesivir produces no meaningful impact on survival,” Martin Landray, an Oxford University professor who led other coronavirus treatment research, said in a statement.

“This is a drug that has to be given by intravenous infusion for five to 10 days,” and costs about $2,550 per treatment course, he said. “COVID affects millions of people and their families around the world. We need scalable, affordable and equitable treatments.”

Dr. Margaret Harris, a WHO spokeswoman, attributed the difference in the conclusions of the two studies to the fact WHO’s was larger.

“It’s just a much higher-powered study,” she said. “It’s quadruple the number of people in all the other studies.”

Results Are Inconsistent With More Rigorous Studies and Have Not Been Fully Reviewed or Published

However, Dr. Andre Kalil, a University of Nebraska infectious disease specialist who helped lead the U.S. remdesivir study, said the WHO one was poorly designed, which makes its conclusions less reliable. Patients and doctors knew what treatment they were using, there was no placebo infusion to help avoid biased reporting of risks or benefits, there was little information about the severity of patients’ symptoms when treatments began and a lot of missing data, he said.

“Poor quality study design cannot be fixed by a large sample size, no matter how large it is,” Kalil wrote in an email.

Furthermore, the WHO study tested 10 days of remdesivir, so some patients may have been hospitalized longer than they needed to be just to finish treatment, making their length of stay look bad in comparison to others getting usual care.

Remdesivir’s maker, Gilead Sciences, said in a statement that the results are inconsistent with more rigorous studies and have not been fully reviewed or published.

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

US Supreme Court Preserves Key Element of Obamacare

DON'T MISS

US Supreme Court Lets Parents Take Kids Out of Classes With LGBT Storybooks

DON'T MISS

Fresno Unified Trustees Will Get Automatic Raises on Tuesday

DON'T MISS

Alleged ‘Fake’ ICE Agents Charged. Fresno Court Date Set

DON'T MISS

In Win for Trump, US Supreme Court Limits Judges’ Power to Block Birthright Citizenship Order

DON'T MISS

California’s Newsom Sues Fox News for $787 Million for Defamation Over Trump Call

DON'T MISS

Motorcycle Collides With Tractor in Fatal Fresno County Collision

DON'T MISS

Ringo Is Ready to Rock Your World With ‘Pawsitive’ Vibes!

DON'T MISS

Calwa Park Sitting on $7.4M in Grants. Where is New Pool, Other Upgrades?

DON'T MISS

Valley Crime Stoppers’ Most Wanted Person of the Day: Teisha Zonnette Thomas

UP NEXT

Bill Moyers, Broadcaster and LBJ’s White House Press Secretary, Dies at 91

UP NEXT

Tesla Executive, Elon Musk Confidant Leaves EV Maker, Bloomberg News Reports

UP NEXT

How a Birthday Boat Ride on Lake Tahoe Turned Tragic

UP NEXT

Cuomo Concedes to Mamdani in New York City Democratic Mayoral Contest

UP NEXT

Mamdani Holds Lead Over Cuomo in Democratic Primary for NYC Mayor

UP NEXT

Clovis Man Sentenced to 8 Years in Federal Prison in Deadly Fentanyl Case

UP NEXT

Victims Identified as Death Toll Climbs to 8 in Lake Tahoe Boating Tragedy

UP NEXT

Florida to Build ‘Alligator Alcatraz’ Detention Center for Migrants in Everglades

UP NEXT

Americans Worry Conflict With Iran Could Escalate, Reuters/Ipsos Poll Finds

UP NEXT

Advisory Warns of ‘Heightened Threat Environment’ in US After Iran Strikes

Alleged ‘Fake’ ICE Agents Charged. Fresno Court Date Set

2 hours ago

In Win for Trump, US Supreme Court Limits Judges’ Power to Block Birthright Citizenship Order

2 hours ago

California’s Newsom Sues Fox News for $787 Million for Defamation Over Trump Call

2 hours ago

Motorcycle Collides With Tractor in Fatal Fresno County Collision

2 hours ago

Ringo Is Ready to Rock Your World With ‘Pawsitive’ Vibes!

2 hours ago

Calwa Park Sitting on $7.4M in Grants. Where is New Pool, Other Upgrades?

3 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Teisha Zonnette Thomas

3 hours ago

Fourth of July Celebrations Begin Saturday. Here’s Your Fresno Area Guide

4 hours ago

Hawaiian Airlines Hit by Cyber Attack

19 hours ago

US House Committee Subpoenas Harvard Over Tuition Costs

19 hours ago

US Supreme Court Preserves Key Element of Obamacare

WASHINGTON — The U.S. Supreme Court on Friday preserved a key element of the Obamacare law that helps guarantee that health insurers cover p...

1 minute ago

Obamacare Sign in San Ysidro, California
1 minute ago

US Supreme Court Preserves Key Element of Obamacare

Pride Flags Fly in New York
30 minutes ago

US Supreme Court Lets Parents Take Kids Out of Classes With LGBT Storybooks

1 hour ago

Fresno Unified Trustees Will Get Automatic Raises on Tuesday

2 hours ago

Alleged ‘Fake’ ICE Agents Charged. Fresno Court Date Set

Olga Urbina carries baby Ares Webster as demonstrators rally on the day the Supreme Court justices hear oral arguments over U.S. President Donald Trump's bid to broadly enforce his executive order to restrict automatic birthright citizenship, during a protest outside the U.S. Supreme Court in Washington, D.C., U.S., May 15, 2025. (Reuters File)
2 hours ago

In Win for Trump, US Supreme Court Limits Judges’ Power to Block Birthright Citizenship Order

California Governor Gavin Newsom speaks to the press after a hearing on the use of National Guard troops amid federal immigration sweeps, at the California State Supreme Court in San Francisco, California, U.S., June 12, 2025. (Reuters FIle)
2 hours ago

California’s Newsom Sues Fox News for $787 Million for Defamation Over Trump Call

fresno
2 hours ago

Motorcycle Collides With Tractor in Fatal Fresno County Collision

Ringo Is GV Wire's Adoptable Pet of the Week, June 27, 2025
2 hours ago

Ringo Is Ready to Rock Your World With ‘Pawsitive’ Vibes!

Help continue the work that gets you the news that matters most.

Search

Send this to a friend